| Species |
Human |
| Protein Construction |
LILRB2/CD85d/ILT4 (Gln22-His458)_x000D_
Accession # Q8N423-1 |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LILRB2/CD85d/ILT4 mFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiLILRB2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
73.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. |
| Synonyms |
CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
